These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7528391)

  • 1. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine therapies for symptomatic benign prostatic hyperplasia.
    Oesterling JE
    Urology; 1994 Feb; 43(2 Suppl):7-16. PubMed ID: 7509536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical management of prostatic diseases.
    Schlegel PN
    Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsurgical treatment of prostatic hyperplasia.
    Geller J
    Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The function and the role of aromatase inhibitors in the treatment of BPH.
    el Etreby MF; Habenicht UF
    Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389
    [No Abstract]   [Full Text] [Related]  

  • 6. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiandrogen therapy of benign prostatic hyperplasia--review of the agents evaluation of the clinical results].
    Kanimoto Y; Okada K
    Hinyokika Kiyo; 1991 Nov; 37(11):1423-8. PubMed ID: 1722627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia. Hormonal treatment.
    McConnell JD
    Urol Clin North Am; 1995 May; 22(2):387-400. PubMed ID: 7539183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacotherapy in benign prostatic hyperplasia].
    Hauri D
    Ther Umsch; 1995 Jun; 52(6):378-82. PubMed ID: 7541566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.